PCN13 Cost-Effectiveness Analysis of Nilotinib Versus Dasatinib in Patients With Imatinib-Resistant or Imatinib-Intolerant Chronic Myeloid Leukemia (CML)
Jun 1, 2012, 00:00
10.1016/j.jval.2012.03.1131
https://www.valueinhealthjournal.com/article/S1098-3015(12)01196-5/fulltext
Title :
PCN13 Cost-Effectiveness Analysis of Nilotinib Versus Dasatinib in Patients With Imatinib-Resistant or Imatinib-Intolerant Chronic Myeloid Leukemia (CML)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(12)01196-5&doi=10.1016/j.jval.2012.03.1131
First page :
A209
Section Title :
Cancer
Open access? :
No
Section Order :
645